- Home
- HDL vs IMTX Comparison
HDL vs IMTX Comparison
Compare HDL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- IMTX
- Stock Information
- Founded
- HDL 2016
- IMTX N/A
- Country
- HDL Singapore
- IMTX Germany
- Employees
- HDL N/A
- IMTX N/A
- Industry
- HDL Restaurants
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HDL Consumer Discretionary
- IMTX Health Care
- Exchange
- HDL Nasdaq
- IMTX Nasdaq
- Market Cap
- HDL 959.6M
- IMTX 1.1B
- IPO Year
- HDL 2024
- IMTX N/A
- Fundamental
- Price
- HDL $16.02
- IMTX $8.17
- Analyst Decision
- HDL
- IMTX Strong Buy
- Analyst Count
- HDL 0
- IMTX 3
- Target Price
- HDL N/A
- IMTX $17.50
- AVG Volume (30 Days)
- HDL 20.6K
- IMTX 500.2K
- Earning Date
- HDL 11-25-2024
- IMTX 11-26-2024
- Dividend Yield
- HDL N/A
- IMTX N/A
- EPS Growth
- HDL N/A
- IMTX N/A
- EPS
- HDL 0.03
- IMTX N/A
- Revenue
- HDL $734,530,000.00
- IMTX $75,935,926.00
- Revenue This Year
- HDL $19.69
- IMTX $54.20
- Revenue Next Year
- HDL $14.20
- IMTX N/A
- P/E Ratio
- HDL $60.80
- IMTX N/A
- Revenue Growth
- HDL 15.00
- IMTX N/A
- 52 Week Low
- HDL $13.94
- IMTX $7.94
- 52 Week High
- HDL $30.00
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- IMTX 24.77
- Support Level
- HDL N/A
- IMTX $8.39
- Resistance Level
- HDL N/A
- IMTX $8.81
- Average True Range (ATR)
- HDL 0.00
- IMTX 0.34
- MACD
- HDL 0.00
- IMTX -0.04
- Stochastic Oscillator
- HDL 0.00
- IMTX 14.89
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.